Regulation of Ethics Committee Approval for Genetic Trials in China

1. Introduction

China regulates ethics committee approval for genetic trials through a combination of bioethics rules, clinical research regulations, human genetic resources legislation and criminal law. These rules aim to protect research participants, preserve human dignity, prevent genetic discrimination and ensure that genetic technologies are developed responsibly.

Genetic trials include gene therapy, genome editing, gene-based diagnosis, human genetic testing and research involving human biological samples or genetic information. Research involving embryos, reproductive cells or heritable genome editing raises particularly serious ethical concerns because its consequences may extend to future generations.

The central legal principle is that ethical approval is a prerequisite for covered human life-science and medical research, but ethical approval alone does not authorise every genetic experiment. Other regulatory permissions may also be required.

China's principal framework includes the Measures for Ethical Review of Life Sciences and Medical Research Involving Humans (2023), the Biosecurity Law (2021), the Regulations on the Administration of Human Genetic Resources (2019), the Civil Code and applicable drug and clinical-trial rules. The 2023 Measures expressly cover research involving human participants, biological samples and information data.

National Health Commission

+1

2. Legal framework governing ethics approval

A. Measures for Ethical Review of Life Sciences and Medical Research Involving Humans, 2023

Issued jointly by the National Health Commission, Ministry of Education, Ministry of Science and Technology and National Administration of Traditional Chinese Medicine on 18 February 2023, these Measures are a central instrument governing ethics review in China.

They apply to covered research conducted by medical institutions, universities and research institutes within China. Their scope includes research into human reproduction and development, disease prevention and treatment, new technologies tested on humans, and research using human biological samples and information.

The principal requirements are:

Institutional ethics committees: Relevant institutions must establish ethics review committees and provide the resources necessary for independent review.

Prior approval: Research requiring ethics review cannot commence before approval is obtained.

Scientific validity: The committee must consider whether the research design is scientifically sound and whether the anticipated benefits justify the risks.

Informed consent: Participants must receive adequate information and participate voluntarily.

Continuing supervision: Approved studies remain subject to follow-up review, adverse-event reporting and possible suspension or termination.

Accountability: Research institutions must maintain appropriate records and ensure compliance with the approved protocol.

The Measures also require institutions to provide ethics education and training for relevant researchers and research-management personnel.

National Health Commission

+1

B. Measures for Ethical Review of Biomedical Research Involving Humans, 2016

The 2016 Measures established an earlier institutional review framework for biomedical research involving humans. They required ethics committees to protect participants' rights, review research protocols, assess informed-consent procedures and monitor approved projects.

The 2023 Measures provide a broader framework covering life-science research and research institutions beyond the earlier medical-institution focus. The 2016 rules remain important to understanding the development of China's regulatory system, but their application must be assessed alongside the later framework and any applicable replacement or transitional provisions.

中华人民共和国国家卫生健康委员会

+1

C. Regulations on the Administration of Human Genetic Resources, 2019

The Human Genetic Resources Regulations, effective from 1 July 2019 and subsequently amended, are particularly important for genetic trials. They distinguish between:

Human genetic resource materials: Human organs, tissues, cells and other materials containing human genetic material.

Human genetic resource information: Data derived from such materials, including relevant genetic information.

Article 9 requires activities involving the collection, preservation, use or external provision of Chinese human genetic resources to comply with ethical principles and applicable ethics-review requirements. It also protects privacy and requires prior informed consent.

International collaborative research may require additional regulatory approval or filing, depending on the activity. The applicable rules also regulate the provision of genetic information abroad and the transfer of physical genetic materials outside China. Ethics committee approval therefore does not automatically satisfy human genetic resources requirements.

nhc.gov.cn

+1

3. Procedure for ethics committee approval

The approval process for a genetic trial generally involves the following stages.

Preparation of the research protocol

Researchers must describe the scientific objectives, genetic techniques, participant-selection criteria, foreseeable risks, potential benefits, sample-handling procedures, data-protection arrangements and follow-up plans.

Submission to the ethics committee

The institution submits the protocol, investigator qualifications, relevant supporting scientific evidence, participant information sheets and informed-consent documents. Additional documents may be required for gene therapy, genome editing or research involving reproductive material.

Independent ethical assessment

The committee evaluates scientific validity, proportionality of risk and benefit, participant selection, privacy, consent, conflicts of interest and safeguards for vulnerable participants. Researchers should disclose uncertainties and explain how adverse consequences will be managed.

Decision and required modifications

The committee may approve the study, reject it, request amendments or further review, or suspend or terminate an approved project where warranted. Approval must not be treated as permission to depart from the reviewed protocol.

Regulatory authorisation and continuing review

Depending on the project, separate drug-trial authorisation, human genetic resources approval or filing, institutional permissions and other regulatory requirements may apply. Serious adverse events and material protocol changes must be handled under the applicable reporting and review requirements.

The 2023 Measures establish the central framework for ethics review and ongoing oversight. The Human Genetic Resources Regulations separately govern relevant genetic materials, information and international cooperation.

National Health Commission

+1

4. Informed consent and protection of participants

Informed consent is a substantive legal and ethical safeguard, not merely a signed form. For genetic trials, participants should understand the experimental nature of the intervention, foreseeable medical risks, uncertainties about long-term effects, privacy arrangements and the intended use of their samples and genetic data.

Consent documentation should explain whether samples or data will be stored for future research, shared with collaborators, transferred internationally or used for purposes beyond the original project. Researchers must comply with the applicable requirements governing changes in purpose and further use.

The risks of genetic research may extend beyond the individual participant. Genetic information can reveal familial relationships, hereditary disease risks or information about relatives who have not participated in the study. Ethics committees should therefore scrutinise confidentiality, data access, retention and the possibility of re-identification.

Where research involves embryos or interventions capable of producing heritable genetic changes, the committee must consider the interests of future children and the potentially irreversible consequences of the intervention. Ordinary consent from prospective parents cannot, by itself, resolve every ethical concern.

5. Relevant cases and legal precedents

A. He Jiankui human gene-editing case (2019)

The most significant Chinese criminal case concerning reproductive human genome editing arose from the experiments associated with scientist He Jiankui.

In November 2018, He announced that genetically edited babies had been born following experiments involving the CCR5 gene. Investigations found serious regulatory and ethical violations, including falsification of an ethics-review certificate, recruitment of couples for assisted reproduction and embryo editing without adequate verification of safety and effectiveness.

On 30 December 2019, the Nanshan District People's Court in Shenzhen convicted He and two collaborators of illegal medical practice. He received three years' imprisonment and a fine of RMB 3 million. The other defendants also received custodial sentences and fines.

English.news.cn

+1

Legal significance: The case demonstrates that an ethics certificate cannot legitimise an unlawful experiment, especially when the certificate is fabricated or the research proceeds outside lawful medical and regulatory controls. It also shows that researchers may face criminal liability, rather than merely institutional disciplinary action.

This was a criminal judgment, not simply an administrative ethics dispute. Its significance lies in the court's application of existing criminal and medical-regulatory law to reproductive genome-editing conduct.

B. National Health Commission investigation (2019)

Following the announcement, the National Health Commission reported that the research seriously violated Chinese laws, regulations and ethical principles. The investigation identified deliberate evasion of oversight and the use of falsified documents.

National Health Commission

+1

Legal significance: The investigation illustrates the importance of verifying an ethics committee's actual decision and institutional authority. A document presented by a researcher cannot substitute for a genuine review by a competent committee.

This was an official investigation, not a separate judicial precedent. It nevertheless provides important evidence of how Chinese authorities respond to suspected violations of genetic-research safeguards.

C. Judicial position on ethics committee approval

The He Jiankui prosecution remains the clearest reported Chinese criminal case directly connected with reproductive genome editing. It should not be inaccurately described as establishing a comprehensive judicial test for every genetic trial.

No separate reported judgment is identified here that establishes a universal judicial standard for all ethics committee approvals under the 2023 Measures. Consequently, the principal rules governing routine genetic trials continue to arise from legislation, administrative regulations and ethics-review instruments.

6. Liability for non-compliance

Failure to comply with applicable requirements can result in several forms of liability:

Criminal liability: Where the conduct satisfies an offence under Chinese criminal law, as demonstrated by the He Jiankui prosecution.

Administrative consequences: Depending on the violation, regulators may impose penalties, revoke improperly obtained permissions or restrict research activities.

Institutional disciplinary action: Universities, hospitals and research institutes may investigate misconduct and restrict researchers' responsibilities.

Civil liability: Participants may seek remedies where unlawful conduct causes injury or infringes legally protected rights.

Research suspension or termination: Ethics committees and competent authorities may intervene to protect participants and prevent further harm.

The precise consequences depend on the applicable legal provision, the nature of the violation and the evidence establishing responsibility.

7. Conclusion

China's regulation of ethics committee approval for genetic trials combines institutional ethics review, informed consent, scientific-risk assessment, genetic-resource protection and legal accountability. The 2023 Measures establish the general framework for human life-science and medical research, while the Human Genetic Resources Regulations address the collection, use and sharing of genetic materials and information.

The He Jiankui case demonstrates the consequences of falsifying ethical approval and conducting reproductive genome-editing experiments outside lawful controls. The broader legal lesson is that genuine ethics committee approval, valid informed consent and compliance with all additional regulatory requirements are separate but complementary obligations. For high-risk genetic research, satisfying only one of these obligations is insufficient.